Immodulon, the immuno-oncology company, is pleased to announce the appointment of Dr Jaap Kampinga as its Chief Scientific Officer. He will work closely with COO Graham Burton and the Immodulon Board to realise the company’s potential as leaders in cancer immunotherapy.

Jaap’s career to date has included academic, senior R&D, CEO and Chairman roles in various medical companies, and he has been CEO of two other drug development companies with drug compounds derived from bacteria. He has also served as a senior partner at a London-based investment boutique firm involved in starting, building and organizing finance for early stage medical companies.